Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: January 25, 2017
Key Event: On January 4, 2017, Abbott Laboratories completed the acquisition of St. Jude Medical, Inc.
Financial Metrics
This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The document focuses on the structural changes to financial reporting resulting from the acquisition.
Material Changes
Beginning with the first quarter of 2017, Abbott's cardiovascular and neuromodulation (ACN) business will be restructured to include its historical Vascular Products segment and the businesses of St. Jude Medical, Inc. Sales results for the ACN business will be reported in three new categories:
- Rhythm Management and Heart Failure: Includes pacemakers, ICDs, cardiac resynchronization therapy, atrial fibrillation products, ventricular assist devices, and the CardioMEMS HF system.
- Cardiovascular and Structural Heart: Includes coronary, endovascular, and vessel closure devices, diagnostic imaging, percutaneous heart pumps, heart valve replacement/repair, patent foramen ovale closure, and left atrial appendage closure products.
- Neuromodulation: Includes spinal cord stimulation, dorsal root ganglion stimulation, and deep brain stimulation products.
Comparable revenue data for each product category for 2016 is referenced in Exhibit 99.1 but is not included in the text of this filing.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard legal disclaimer. The document states that the information contained herein shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Key Facts for Investor Verification
- Verify the specific comparable revenue figures for 2016 by product category in Exhibit 99.1, as these are not listed in the main text.
- Confirm the integration timeline and operational impact of the St. Jude Medical acquisition on the new ACN business segment.
- Review subsequent filings for the first quarter of 2017 to see the initial financial results under the new reporting structure.